These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 36471232)

  • 1. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JGH Open; 2024 Oct; 8(10):. PubMed ID: 39403113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
    Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
    J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
    Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
    Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
    Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
    McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
    Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.
    Liu Q; Zhao G; Li Q; Wu W; Zhang Y; Bian H
    BMC Gastroenterol; 2022 Nov; 22(1):471. PubMed ID: 36402947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center.
    Guan C; Fu S; Zhen D; Yang K; An J; Wang Y; Ma C; Jiang N; Zhao N; Liu J; Yang F; Tang X
    J Diabetes Res; 2022; 2022():8429847. PubMed ID: 35127953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
    PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus.
    Cheng YM; Wang SW; Wang CC; Kao JH
    Tzu Chi Med J; 2024; 36(4):425-432. PubMed ID: 39421499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of subclinical carotid artery atherosclerosis assessed by carotid ultrasound with nonalcoholic fatty liver disease fibrosis score in young and middle-aged men.
    Durak H; Çetin M; Emlek N; Özyıldız AG; Ergül E; Duman H
    Int J Cardiovasc Imaging; 2024 Sep; 40(9):1979-1986. PubMed ID: 39012403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
    Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
    Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.